Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although most treatment research on bipolar disorder has focused on mania, depressive episodes occur more frequently among patients with bipolar disorder. Here, we report the results of 2 identically designed, 8-week, multicenter, randomized, double-blind, placebo-controlled studies (CN138-096 and CN138-146) to evaluate the efficacy and safety of aripiprazole monotherapy in outpatients with bipolar I disorder experiencing a major depressive episode without psychotic features. Patients were randomized to placebo or aripiprazole (initiated at 10 mg/d, then flexibly dosed at 5-30 mg/d based on clinical effect and tolerability). The primary end point was mean change from baseline to Week 8 (last observation carried forward) in the Montgomery-Asberg Depression Rating Scale total score. In Studies 1 and 2, respectively, 186 and 187 patients were randomized to aripiprazole, and 188 and 188 to placebo. Although statistically significant differences were observed during Weeks 1 to 6, aripiprazole did not achieve statistical significance versus placebo at Week 8 in either study in the change in Montgomery-Asberg Depression Rating Scale total (primary end point). In addition, despite early statistical separation on the Clinical Global Impressions Bipolar Version Severity of Illness-Depression score (key secondary end point), aripiprazole was not superior to placebo at end point. Aripiprazole was associated with a higher incidence of akathisia, insomnia, nausea, fatigue, restlessness, and dry mouth versus placebo. More patients discontinued with aripiprazole versus placebo in Study 1 (46.8% vs 35.1%) and Study 2 (41.2% vs 29.8%). Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aripiprazole monotherapy failed to separate from placebo in two bipolar depression trials.292”
In the citing paper
“except for aripiprazole trials which have shown a 6-wk limited superiority compared to placebo, decreasing its effect size at endpoint (Thase et al. 2008).”
From Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis (2010) · cites this paper as Thase et al. 2008
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908 · cited 2×
“However, the mean improvements in Montgomery–Åsberg Depression Rating Scale (MADRS) scores were significantly greater with OFC compared with either olanzapine monotherapy of placebo.(5) Most recently, quetiapine was approved (in 2006) by the FDA for the treatment of depressive episodes associated with bipolar disorder.”
BackgroundResultSelf-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 4×
“Most recently, quetiapine was approved (in 2006) by the FDA for the treatment of depressive episodes associated with bipolar disorder.(6,7) In two 8-week double-blind studies, Original Contribution”
BackgroundResultInfluentialKane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624 · cited 2×
“0% of aripiprazole-treated patients, severity of akathisia (including those leading to discontinuation) was most frequently rated as mild to moderate, and the incidence of akathisia in these studies was higher than observed in previous studies in patients with bipolar I mania or schizophrenia/schizoaffective disorder.…”
BackgroundResultSelf-citationPotkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591 · cited 1×
“The dose range was chosen based on results of aripiprazole studies in patients with bipolar I disorder (manic or mixed) or schizophrenia/schizoaffective disorder in which aripiprazole 15 to 30 mg/d demonstrated robust efficacy and was generally well tolerated.(12,13,23,24,26) It is possible that the dosing regimen use…”
BackgroundSelf-citationThase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 4×
“Most recently, quetiapine was approved (in 2006) by the FDA for the treatment of depressive episodes associated with bipolar disorder.(6,7) In two 8-week double-blind studies, Original Contribution”
BackgroundResultInfluentialSelf-citationThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Keck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501 · cited 2×
“0% of aripiprazole-treated patients, severity of akathisia (including those leading to discontinuation) was most frequently rated as mild to moderate, and the incidence of akathisia in these studies was higher than observed in previous studies in patients with bipolar I mania or schizophrenia/schizoaffective disorder.…”
BackgroundResultSelf-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
“In a report of two identically designed, eight-week, multicenter, double-blind RCTs, aripiprazole (5–30 mg ⁄d) monotherapy was no more effective than placebo in 749 patients with bipolar depression and was associated with higher incidence of side effects and higher discontinuation rates than placebo (Level 1, negative…”
BackgroundAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metadata
- Authors
- Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R.
- Affiliations
- Otsuka (United States) (US)
- Northwest Clinical Research Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Thase, Michael E.
- McQuade, Robert D.
- Carson, William H.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-02
- Volume
- 28
- Issue
- 1
- Pages
- 13-20
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2032446177
- Cited by
- 251
- References
- 29
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 9 · 2020: 12 · 2019: 9 · 2018: 10 · 2017: 5 · 2016: 18 · 2015: 15 · 2014: 18 · 2013: 20 · 2012: 16
- FWCI
- 22.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- aripiprazole, bipolar I depression, monotherapy, atypical antipsychotics, placebo comparison, akathisia, treatment efficacy, treatment discontinuation, Montgomery-Asberg Depression Rating Scale
- MeSH terms
- Aripiprazole, Adolescent, Adult, Aged, Bipolar Disorder, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Piperazines, Antipsychotic Agents, Quinolones, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181618eb4
- The paper
- Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008). Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181618eb4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.